Discovery and Optimization of Triazolopyridazines as Potent and Selective Inhibitors of the c-Met Kinase
- 22 April 2008
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (10), 2879-2882
- https://doi.org/10.1021/jm800043g
Abstract
Tumorigenesis is a multistep process in which oncogenes play a key role in tumor formation, growth, and maintenance. MET was discovered as an oncogene that is activated by its ligand, hepatocyte growth factor. Deregulated signaling in the c-Met pathway has been observed in multiple tumor types. Herein we report the discovery of potent and selective triazolopyridazine small molecules that inhibit c-Met activity.Keywords
This publication has 8 references indexed in Scilit:
- c-Met Inhibitors with Novel Binding Mode Show Activity against Several Hereditary Papillary Renal Cell Carcinoma-related MutationsJournal of Biological Chemistry, 2008
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic MechanismsCancer Research, 2007
- Targeting Tyrosine Kinases in Cancer: The Second WaveScience, 2006
- Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752Proceedings of the National Academy of Sciences, 2006
- Hereditary Papillary Renal Carcinoma Type ICurrent Molecular Medicine, 2004
- Met, metastasis, motility and moreNature Reviews Molecular Cell Biology, 2003
- Tyrosine kinase receptor indistinguishable from the c-met proteinNature, 1989